Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCyp c 1 SCIT for Fish Allergy
NCT02382718Phase 2Completed
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in fish allergy comparing FAST fish mCyp c 1 with Placebo (2 arms). Primary endpoint: Efficacy of subcutaneous immunotherapy with mCyp c 1 for the treatment of fish allergy (change from baseline in the threshold of fish protein that induces an allergic reaction) at 7 months. Started Oct 2015; status: completed.
02
Drugs
mutant carp parvalbumin
03
Conditions
fish allergy
Beyond the preview
Go deeper on NCT02382718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382718.